Brazil's SUS & ANVISA: A Guide for Korean MedTech

This episode provides a strategic overview for Korean medical device companies targeting the Brazilian market. We explore the critical process of navigating Brazil's Unified Health System (SUS) to gain market access and secure reimbursement. The discussion covers the key differences between Brazil's public tender process and Korea's HIRA system, recent modernizing changes by ANVISA that impact international companies, and the strategic importance of understanding both the public and private healthcare sectors for successful hospital and institutional sales. Key Questions: - How can Korean MedTech firms tap into Brazil's massive public healthcare market? - What are the key differences between SUS public tenders and HIRA reimbursement? - Have recent ANVISA changes made it easier for foreign companies to win bids? - Why is a local strategy essential for navigating Brazilian procurement? - What role does the private healthcare sector play in a Brazil market entry plan? - How do price negotiations work within the Brazilian public system? Pure Global provides MedTech and IVD companies with end-to-end solutions for entering complex markets like Brazil. Our experts develop efficient regulatory strategies, act as your local representative for ANVISA registration, and use advanced AI to compile and manage technical submissions. We help you navigate public tender requirements and post-market surveillance, ensuring you can access the Brazilian market faster and maintain compliance. For more information on how we can accelerate your global expansion, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.